Respiratory Inhalers Market Scope And Analysis

Report Code : TIPRE00003093
Category : Medical Device

Status : Published
No. of Pages : 254

Buy Now

Respiratory Inhalers Market Analysis, Size, and Growth (2023-2028)

Buy Now

Respiratory Inhalers Market Report Scope

Report Attribute	Details
Market size in 2022	US$ 31.14 Billion
Market Size by 2028	US$ 43.45 Billion
Global CAGR (2022 - 2028)	5.7%
Historical Data	2020-2021
Forecast period	2023-2028
Segments Covered	By Product Type Nebulizers Metered Dose Inhalers Dry Powder Inhalers By Technology Manually Operated Inhalers Digitally Operated Inhalers By Disease Indication Asthma COPD Pulmonary Arterial Hypertension
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	AstraZeneca Plc Beximco Pharmaceuticals Ltd Boehringer Ingelheim International GmbH Cipla Ltd GSK Plc Koninklijke Philips NV OMRON Corp PARI Respiratory Equipment Inc Teva Pharmaceutical Industries Ltd

Disease Indication-Based Insights

Based on disease indication, the global respiratory inhalers market is segmented into asthma, COPD, pulmonary arterial hypertension, and others. The asthma segment held the largest share of the market in 2022 and is expected to grow at the highest CAGR during the forecast period.

Inorganic and organic strategies such as mergers and acquisitions are highly adopted by companies in the respiratory inhalers market. A few recent key market developments are listed below:

In September 2022, Beximco Pharmaceuticals launched ONRIVA TRIO BEXICAP, which is a dry inhaler capsule. ONRIVA TRIO BEXICAP is the preparation of Indacaterol (150 µg), Glycopyrronium (50 µg), and Mometasone (160 µg). It works in 3 ways to control asthma symptoms. Indacaterol and Glycopyrronium help the muscles of lung airways to stay relaxed to prevent bronchoconstriction, while Mometasone helps to decrease inflammation. ONRIVA TRIO BEXICAP is indicated as maintenance therapy in severe persistent asthma.
In June 2021, Cipla announced that it had received final approval for its Abbreviated New Drug Application (ANDA) for Arformoterol Tartrate Inhalation Solution 15 mcg/2 mL from the US Food and Drug Administration. Cipla's Arformoterol Tartrate Inhalation Solution 15 mcg/2 mL is an AN-rated generic therapeutic equivalent version of Sunovion Pharmaceuticals Inc.'s Brovana.
In February 2022, AstraZeneca and Honeywell announced their plans to partner for the development of next-generation respiratory inhalers using the propellant HFO-1234ze, which has up to 99.9% less Global Warming Potential (GWP) than propellants currently used in respiratory medicines.
In January 2023, FDA approved Airsupra [pressurized metered-dose inhaler (pMDI)] in the US for the as-needed treatment or prevention of bronchoconstriction. Airsupra is a first-in-class, pressurized metered-dose inhaler (pMDI), fixed-dose combination rescue medication containing albuterol, a short-acting beta2-agonist (SABA), and budesonide, an anti-inflammatory inhaled corticosteroid (ICS) in the US.

Company Profiles

AstraZeneca Plc
Beximco Pharmaceuticals Ltd.
Boehringer Ingelheim International GmbH
Cipla Ltd.
GSK Plc
Koninklijke Philips NV
OMRON Corp
PARI Respiratory Equipment, Inc.
Teva Pharmaceutical Industries Ltd.
OPKO Health, Inc.